The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population
This study was conducted to explore whether the non-synonymous single-nucleotide polymorphisms in SCN9A gene can predict individual basal pain perception and postoperative pain intensity in the general population undergoing upper abdominal surgery. Methods: Patients receiving elective upper abdominal surgery under general anesthesia were recruited into this study. Genotyping of SCN9A was carried out by direct sequencing. The investigators measured their preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO). The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h ,24 h and 48h after operation. And the PCA press frequency and drug consumption were recorded.
|Official Title:||The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population|
- PCA press frequency and opioid consumption dose 48h after operation. [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]
- The visual analog scale 48h after operation. [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]The visual analog scale (VAS) is used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h,24 h and 48h after operation.
- Preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO) [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
Heparin anti-coagulated blood (2 ml) was collected from the central venous during the operation and all blood samples were stored at -80℃. Genomic DNA was extracted from the blood samples using a guanidinium isothiocyanate method.
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
Patients with the following diseases were excluded: known history of chronic pain, psychiatric diseases or communication disorders, diabetes mellitus, severe cardiovascular diseases, kidney or liver diseases with poor hepatic function, alcohol or drug abuse, heavy smoker, pregnancy or at the lactation period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01507493
|Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology|
|Wuhan, Hubei, China, 430030|
|Study Director:||Zhang Xianwei, Doctor||Huazhong University of Science and Technology|